Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Core Points - Oculis Holding AG announces the continuation of the Ramin Tadayoni Award in collaboration with EURETINA to honor the legacy of Professor Tadayoni, focusing on innovative research in retinal diseases [1][2] - The award provides €30,000 for research support and an additional €5,000 for the candidate, aimed at postgraduate scholars in retina research, with applications open until May 12, 2025 [3] - The inaugural recipient of the award in 2024 was Dr. Andrea Govetto, who is developing a computational model for macular edema [4] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema, Privosegtor for acute optic neuritis, and Licaminlimab for dry eye disease [6] - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [6]